| Description |
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs[1][2].
|
| Related Catalog |
|
| In Vivo |
Bedinvetmab (0.5-1 mg/kg; s.c. for 28 d) 减轻与犬骨关节炎相关的疼痛[1]。 Bedinvetmab (1 mg/kg; s.c. monthly; 3× and 10× dose multiples) 与 Carprofen (HY-B1227) 共同给药，在正常实验室比格犬中耐受性良好[2]。
|
| References |
[1]. Corral MJ, et, al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021 Nov;48(6):943-955. [2]. Krautmann M, et, al. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021 Oct;276:105733.
|
